CN113272330A - 一种双特异抗体 - Google Patents

一种双特异抗体 Download PDF

Info

Publication number
CN113272330A
CN113272330A CN202080006179.5A CN202080006179A CN113272330A CN 113272330 A CN113272330 A CN 113272330A CN 202080006179 A CN202080006179 A CN 202080006179A CN 113272330 A CN113272330 A CN 113272330A
Authority
CN
China
Prior art keywords
bispecific antibody
msh
antibody
binding domain
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080006179.5A
Other languages
English (en)
Other versions
CN113272330B (zh
Inventor
王峰
郑花鸯
张雨菡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nantong Yichen Biomedical Technology Co ltd
Original Assignee
Shanghai Yichen Pharmaceutical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Yichen Pharmaceutical Technology Co ltd filed Critical Shanghai Yichen Pharmaceutical Technology Co ltd
Publication of CN113272330A publication Critical patent/CN113272330A/zh
Application granted granted Critical
Publication of CN113272330B publication Critical patent/CN113272330B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

提供了一种双特异抗体，尤其是一种同时靶向肿瘤细胞表面抗原和免疫检查点蛋白的双特异抗体。该抗体包含靶向第一靶细胞的免疫检查点蛋白的第一结合结构域，和结合至第二靶细胞表面的肿瘤细胞表面抗原第二结合结构域。抗体通过多肽与肿瘤细胞表面抗原的高亲和力结合，将与其融合的针对免疫检查点的片段(例如PD‑L1抗体)聚集到肿瘤细胞上、或其附近以及肿瘤微环境内，发挥效应细胞对肿瘤细胞的特异性杀伤作用。

Description

PCT国内申请，说明书已公开。

Claims (29)

  1. PCT国内申请，权利要求书已公开。
CN202080006179.5A 2019-03-02 2020-02-28 一种双特异抗体 Active CN113272330B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019101578685 2019-03-02
CN201910157868 2019-03-02
PCT/CN2020/077181 WO2020177627A1 (zh) 2019-03-02 2020-02-28 一种双特异抗体

Publications (2)

Publication Number Publication Date
CN113272330A true CN113272330A (zh) 2021-08-17
CN113272330B CN113272330B (zh) 2024-07-26

Family

ID=72338054

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080006179.5A Active CN113272330B (zh) 2019-03-02 2020-02-28 一种双特异抗体

Country Status (2)

Country Link
CN (1) CN113272330B (zh)
WO (1) WO2020177627A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117482246A (zh) * 2022-12-30 2024-02-02 英百瑞(杭州)生物医药有限公司 抗cd33/cll1双特异性抗体-自然杀伤细胞偶联物及其用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113754772A (zh) * 2020-06-02 2021-12-07 三生国健药业（上海）股份有限公司 一种抗pdl1×kdr的双特异性抗体
CN114195900B (zh) * 2020-09-17 2024-02-23 普米斯生物技术(珠海)有限公司 一种抗4-1bb/pd-l1双特异性抗体及其用途
EP4010378A4 (en) * 2020-10-16 2023-07-26 LaNova Medicines Limited ANTICCR8 MONOCLONAL ANTIBODIES AND USES THEREOF
CN114539416A (zh) * 2020-11-26 2022-05-27 盛禾(中国)生物制药有限公司 一种双特异性抗体的层析纯化工艺
WO2023020315A1 (zh) * 2021-08-19 2023-02-23 南京吉盛澳玛生物医药有限公司 靶向pd-l1/pd-1的抗体及其应用

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030108523A1 (en) * 2001-09-05 2003-06-12 Lipton James M. Cancer treatment system
CN101184499A (zh) * 2005-02-23 2008-05-21 阿尔扎公司 活性剂向中枢神经系统的鼻内施用
CN101437540A (zh) * 2004-10-25 2009-05-20 森托科尔公司 结合黑皮质素受体的拟抗体、组合物、方法和用途
WO2015019284A2 (en) * 2013-08-05 2015-02-12 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy
WO2016168361A1 (en) * 2015-04-14 2016-10-20 Polynoma, Llc Polyvalent vaccines and combination therapy for the treatment of melanoma
WO2017174331A1 (en) * 2016-04-07 2017-10-12 Cancer Research Technology Limited Anti cd25 fc gamma receptor bispecific antibodies for tumor specific cell depletion
US20180051085A1 (en) * 2016-06-17 2018-02-22 Immunomedics, Inc. Novel anti-pd-1 checkpoint inhibitor antibodies that block binding of pd-l1 to pd-1
WO2018178123A1 (en) * 2017-03-29 2018-10-04 Glycotope Gmbh BISPECIFIC MUC-1 x PD-L1 ANTIBODIES
CN108697791A (zh) * 2015-11-03 2018-10-23 詹森生物科技公司 特异性结合pd-1的抗体及其用途
CN109153728A (zh) * 2016-03-21 2019-01-04 埃尔斯塔治疗公司 多特异性和多功能分子及其用途

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030108523A1 (en) * 2001-09-05 2003-06-12 Lipton James M. Cancer treatment system
CN101437540A (zh) * 2004-10-25 2009-05-20 森托科尔公司 结合黑皮质素受体的拟抗体、组合物、方法和用途
CN101184499A (zh) * 2005-02-23 2008-05-21 阿尔扎公司 活性剂向中枢神经系统的鼻内施用
WO2015019284A2 (en) * 2013-08-05 2015-02-12 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy
WO2016168361A1 (en) * 2015-04-14 2016-10-20 Polynoma, Llc Polyvalent vaccines and combination therapy for the treatment of melanoma
CN108697791A (zh) * 2015-11-03 2018-10-23 詹森生物科技公司 特异性结合pd-1的抗体及其用途
CN109153728A (zh) * 2016-03-21 2019-01-04 埃尔斯塔治疗公司 多特异性和多功能分子及其用途
WO2017174331A1 (en) * 2016-04-07 2017-10-12 Cancer Research Technology Limited Anti cd25 fc gamma receptor bispecific antibodies for tumor specific cell depletion
US20180051085A1 (en) * 2016-06-17 2018-02-22 Immunomedics, Inc. Novel anti-pd-1 checkpoint inhibitor antibodies that block binding of pd-l1 to pd-1
WO2018178123A1 (en) * 2017-03-29 2018-10-04 Glycotope Gmbh BISPECIFIC MUC-1 x PD-L1 ANTIBODIES

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EVA DAHLÉN等: "Bispecific antibodies in cancer immunotherapy", vol. 6, no. 1, pages 3 - 17 *
YUHAN ZHANG等: "A tumor-targeted immune checkpoint blocker", vol. 116, no. 32, pages 15889, XP055736394, DOI: 10.1073/pnas.1905646116 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117482246A (zh) * 2022-12-30 2024-02-02 英百瑞(杭州)生物医药有限公司 抗cd33/cll1双特异性抗体-自然杀伤细胞偶联物及其用途

Also Published As

Publication number Publication date
WO2020177627A1 (zh) 2020-09-10
CN113272330B (zh) 2024-07-26

Similar Documents

Publication Publication Date Title
CN113272330A (zh) 一种双特异抗体
EP3638700B1 (en) Proteinaceous heterodimer and use thereof
US20210355209A1 (en) Multi-specific binding molecules targeting aberrant cells
CN112533944A (zh) 多特异性结合蛋白及其改进
JP7010487B2 (ja) 抗コチニン抗体が連結したキメラ抗原受容体およびその使用
JP7474235B2 (ja) ＯＸ４０抗原結合部位を含むＦｃ結合断片
CN112638950B (zh) 一种双特异性抗体
US20240067700A1 (en) T-cell modulatory polypeptides and methods of use thereof
KR20210030406A (ko) Cd137 항원-결합 부위를 포함하는 fc 결합 단편
KR20230171465A (ko) 항cldn4-항cd137 이중특이성 항체
KR20190105584A (ko) 암 치료를 위한 병용 요법
WO2023046156A1 (en) Il-2 variants and fusion proteins thereof
CN112041432A (zh) Foxp3靶向剂组合物以及用于过继细胞疗法的使用方法
JP2023541853A (ja) Ｐｄ－１ポリペプチド変異体
US11673930B2 (en) IL10 agonists and methods of use thereof
EP4137510A1 (en) Pd-1 mutant polypeptide, and preparation therefor and use thereof
KR20240040134A (ko) 항체 접합체 및 이의 제조

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20240517

Address after: Room 402, Building 2, No. 109 Yongfu Road, Tangzha Town Street, Chongchuan District, Nantong City, Jiangsu Province, 226000

Applicant after: Nantong Yichen Biomedical Technology Co.,Ltd.

Country or region after: China

Address before: Room 1107-a, building 67, 421 Hongcao Road, Xuhui District, Shanghai 200233

Applicant before: Shanghai Yichen Pharmaceutical Technology Co.,Ltd.

Country or region before: China

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant